Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
50 hedge funds and large institutions have $32.4M invested in Dicerna Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 9 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
4% more funds holding
Funds holding: 48 → 50 (+2)
54% less capital invested
Capital invested by funds: $71.1M → $32.4M (-$38.7M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$1.31M |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$380K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$354K |
| 4 |
Renaissance Technologies
New York
|
+$301K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$178K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
A
Abingworth
London,
United Kingdom
|
-$2.16M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.03M |
| 3 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$758K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$701K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$580K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DCM
51
DAFNA Capital Management
Los Angeles,
California
| – | -$701K | -119,300 | Closed |
|
|
OAM
52
Oxford Asset Management
Oxford,
United Kingdom
| – | -$347K | -59,006 | Closed |
|
|
ACA
53
Avoro Capital Advisors
New York
| – | -$271K | -46,082 | Closed |
|
54
JP Morgan Chase
New York
| – | -$78K | -13,278 | Closed |
|
55
ProShare Advisors
Bethesda,
Maryland
| – | -$77K | -13,089 | Closed |
|
|
CS
56
Credit Suisse
Zurich,
Switzerland
| – | -$60K | -10,245 | Closed |
|
|
TFCP
57
Twin Focus Capital Partners
Boston,
Massachusetts
| – | -$59K | -10,000 | Closed |
|
58
Walleye Trading
New York
| – | -$12K | -2,100 | Closed |
|
DRNA Hedge Fund Activity: Q4 2016 in Review
50 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q4 2016, worth a combined $32.4M — down 54% from $71.1M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new DRNA positions and 9 closed out — a net gain of 2 holders — while 16 added to existing stakes and 13 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $1.31M. The largest seller was Abingworth, cutting an estimated $2.16M.
- 50 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q4 2016, up from 48 in Q3 2016.
- Funds reported $32.4M of Dicerna Pharmaceuticals, Inc. stock for Q4 2016, down 54% quarter-over-quarter.
- 11 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q4 2016 and 9 closed out, a net change of +2 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q4 2016 was 683 Capital Management, an estimated $1.31M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q4 2016 was Abingworth, an estimated $2.16M sold.
Based on aggregated 13F filings for Q4 2016.